Zelluna ASA — Board/Management Information 2021

Oct 8, 2021

Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances

Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances

Oslo, October 8, 2021: Ultimovacs ASA today announced two senior appointments to

its management team: Orla Mc Callion as Head of Regulatory Affairs & QA and Anne

Worsøe as Head of Investor Relations & Communication, both effective October

1, 2021.

As Head of Regulatory Affairs & QA, Orla Mc Callion will manage the strategic

planning and implementation of regulatory procedures across all Ultimovacs'

development products. Orla brings a wealth of industry knowledge with more than

20 years of experience in the pharmaceutical industry, and is an accomplished

scientist and leader within regulatory and clinical development. Orla has

regularly interacted with EMA, FDA and other national Regulatory Authorities for

scientific advice procedures, submissions for serious conditions, orphan

designations and pediatric-related activities and to secure clinical trial

approvals. Previously, Orla was Director of Regulatory Affairs at OxThera AB.

Orla holds a Ph.D. in Pharmacy from Queen's University in Belfast.

Orla commented: "I am delighted to join the Ultimovacs team at this exciting

time and hope to support the company's growth as an innovative and leading

oncology company."

As Head of Investor Relations & Communication Anne Worsøe will oversee the

communication between Ultimovacs' management, investors and the broader public.

With 20 years of experience within the investment industry, she has extensive

knowledge in strategy and business development, internationalization, PR,

branding & communication. Anne was the first CEO of the Norwegian Venture

Capital & Private Equity Association and Venture Partner at Antler, a global

venture capital firm. She spent four years in the USA as Director of Innovation

Norway in San Francisco. Anne has served on the Boards of several early-stage

companies, venture capital funds, private and public limited companies, and

served as an expert jury member at the European Commission's EIC Accelerator

program. Anne holds a Master of Business and Economics from Norwegian Business

School.

Anne commented: "I am honored to join Ultimovacs and to work with an

extraordinary team of visionary scientists and industry leaders, making a real

impact for cancer patients. I am genuinely enthusiastic about the journey ahead

for the company. "

"Ultimovacs can attract highly talented people across many disciplines and

geographies, and we are very excited to welcome Orla and Anne to our team. Both

bring substantial expertise to Ultimovacs at a time when the company is being

increasingly recognized as a global leader in therapeutic cancer vaccines," says

CEO Carlos de Sousa.

About Ultimovacs:

Ultimovacs' mission is to and extend and improve the life of patients by

enabling the immune system to fight cancer. The Company is developing immune-

stimulatory vaccines to treat a broad range of cancers. Ultimovacs' lead

universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present

in over 80% of cancers in all stages of tumor growth. By directing the immune

system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate

an immune system cascade and increase anti-tumor responses. With a broad Phase

II program, Ultimovacs aims to clinically demonstrate UV1's impact in multiple

cancer types in combination with other immunotherapies. Ultimovacs' second

technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET)

platform, combines tumor-specific peptides and adjuvant in the same molecule and

entered Phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO

Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)

Phone: +47 908 92507

Anne Worsøe, Head of IR & Communication

Email: anne.worsoe@ultimovacs.com (mailto:anne.worsoe@ultimovacs.com)

Phone: +47 906 86815